Evidence map›Paper›PMID 36837770›Full record

ArticleMetabolites2023

Cycloguanil and Analogues Potently Target DHFR in Cancer Cells to Elicit Anti-Cancer Activity.

Jennifer I Brown, Peng Wang, Alan Y L Wong, Boryana Petrova, Rosanne Persaud, Sepideh Soukhtehzari, Melanie Lopez McDonald, Danielle Hanke, Josephine Christensen, Petar Iliev and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Metabolites, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Jennifer I BrownFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Peng WangDepartment of Pathology, Boston Children's Hospital, Boston, MA 02115, USA.
Alan Y L WongDepartment of Pathology, Boston Children's Hospital, Boston, MA 02115, USA.
Boryana PetrovaDepartment of Pathology, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0001-9996-9353
Rosanne PersaudFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Sepideh SoukhtehzariFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Melanie Lopez McDonaldDepartment of Hematology and Medical Oncology, Emory University, Atlanta, GA 30322, USA.
Danielle HankeFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Josephine ChristensenFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Petar IlievFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Weiyuan WangDepartment of Hematology and Medical Oncology, Emory University, Atlanta, GA 30322, USA.ORCID 0000-0003-0009-0467
Daniel K EvertonFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Karla C WilliamsFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
David A FrankDepartment of Hematology and Medical Oncology, Emory University, Atlanta, GA 30322, USA.ORCID 0000-0002-7698-8364
Naama KanarekDepartment of Pathology, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-2068-3908
Brent D G PageFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.ORCID 0000-0002-2101-1329
University of British Columbia · CABoston Children's Hospital · USEmory University · USBroad Institute · US

Funding

Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
CIHR PG-461696NIGMS NIH HHS T32 GM007753
6 · The paper itself

Abstract

Dihydrofolate reductase (DHFR) is an established anti-cancer drug target whose inhibition disrupts folate metabolism and STAT3-dependent gene expression. Cycloguanil was proposed as a DHFR inhibitor in the 1950s and is the active metabolite of clinically approved

Indexed as

breast cancercancer therapycycloguanildihydrofolate reductasefolate metabolismSTAT3target engagement

Identifiers

PMID36837770
PMCPMC9961069
OpenAlexW4317506066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.